Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi Files Sakigake-Designated Olipudase Alfa in Japan for Acid Sphingomyelinase Deficiency
October 1, 2021
- Fujifilm, Australian Startup Join Hands for Contract Manufacturing of iPS Cell-Derived Regenerative Medicine Products
October 1, 2021
- Shionogi Chief Expresses Eagerness for COVID-19 Drug Rollout, PII/III to Wrap Up by Year-End
September 30, 2021
- PeptiDream Bags Milestone Payments from Janssen for Licensing Peptide Discovery Platform Technology
September 30, 2021
- Gilead Seeks Label Expansion for Epclusa in Japan
September 29, 2021
- Shionogi Out-Licenses Ultra-Long-Acting HIV Drug to ViiV
September 29, 2021
- Shionogi Kicks Off Japan PII/III Trial for Oral COVID-19 Drug
September 29, 2021
- Eisai/Biogen Begin US Rolling Submission for Alzheimer’s Med Lecanemab
September 28, 2021
- Takeda’s Cell Therapy Alofisel Approved in Japan
September 28, 2021
- ASKA Earns Japan Rights to Takeda’s Relugolix Combo Drug
September 28, 2021
- ASKA Retracts Japan Application for Uterine Fibroid Med Ulipristal
September 28, 2021
- Astellas, Tohoku University Extend Collaboration for New Healthcare Solutions
September 27, 2021
- Startup Headed by Ex-Biogen Japan Chief Working to Develop New Alzheimer’s Drugs Using Photocatalysts
September 27, 2021
- Sawai Now Curbing Shipments for 432 Products
September 24, 2021
- Towa’s Shipment Restriction List Now Expands to 385 Products
September 24, 2021
- RaQualia Grants Global Rights for TRPM8 Blocker to HK Firm
September 24, 2021
- Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
- Skyrizi’s New Dosage Forms Approved in Japan: AbbVie
September 24, 2021
- Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
September 24, 2021
- Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III
September 24, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…